Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes^™

References

• Roots I., Gerloff T., Meisel C., Kirchheiner J., Goldammer M., Kaiser R., et al. Pharmacogenetics‐based new therapeutic concepts. Drug Metabolism Rev 2004; 36: 617–38
   PubMed Web of Science ®Google Scholar
• Daly A. K. Pharmacogenetics of the cytochromes P450. Cur Top Med Chem 2004; 4: 1733–44
   PubMed Web of Science ®Google Scholar
• Kirchheiner J., Brøsen K., Dahl M. L., Gram L. F., Kasper S., Roots I., et al. CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages. Acta Psych Scand 2001; 104: 173–92
   PubMed Web of Science ®Google Scholar
• Wedlund P. J., deLeo J., Lexington K. Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence?. Clin Pharm Ther 2004; 75: 373–5
   PubMed Web of Science ®Google Scholar
• Rau T., Wohlleben G., Wuttke H., Thurauf N., Lunkenmeier J., Lanczik M., et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants – a pilot study. Clin Pharm Ther 2004; 75: 386–93
   PubMed Web of Science ®Google Scholar
• Steimer W., Zopf K., von Amelunxen S., Pfeiffer H., Bachofer J., Popp J., et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP219 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376–85
   PubMed Web of Science ®Google Scholar
• de Leon J., Susce M. T., Pan R. M., Fairchild M., Koch W. H., Wedlund P. J. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychol 2005; 66: 15–27
   Google Scholar
• Ingelman‐Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5: 6–13
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Dahl M‐L., Dalèn P., Al‐Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotrophic drugs. Br J Clin Pharmacol 2002; 53: 111–22
   PubMed Web of Science ®Google Scholar
• Steen V. M., Andreassen O. A., Daly A. K., Tefre T., Børresen A‐L., Idle J. R., et al. Detection of the poor metabolizer‐associated CYP2D6(D) gene deletion allele by long‐PCR technology. Pharmacogenetics 1995; 5: 215–23
   PubMedGoogle Scholar
• Daly A. K., Fairbrother K. S., Andreassen O. A., London S. J., Idle J. R., Steen V. M. Characterization and PCR‐based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996; 6: 319–28
   PubMedGoogle Scholar
• Johansson I. J., Lundquist E., Bertilsson L., Dahl M‐L., Sjöqvist F., Ingelman‐Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825–9
   PubMed Web of Science ®Google Scholar
• Johansson I., Lundqvist E., Dahl M‐L., Ingelman‐Sundberg M. PCR based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996; 6: 351–5
   PubMedGoogle Scholar
• Armstrong M., Idle J. R., Daly A. K. A polymorphic Cfo I site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. Hum Genet 1993; 91: 616–17
   PubMed Web of Science ®Google Scholar
• Broly F., Marez D., Sabbagh N., Legrand M., Millecamps S., Guidice J. M–L., et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995; 5: 373–84
   PubMedGoogle Scholar
• Chou W‐H., Yan F‐X., Robbins‐Weilert D. K., Ryder T. B., Liu W. W., Perbost C., et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype–phenotype relationships. Clin Chem 2003; 49: 542–51
   PubMed Web of Science ®Google Scholar
• Gaedigk A., Gotschall R. R., Forbes N. S., Simon S. D., Kearns G. L., Leeder J. S. Optimization of cytochrome P450D6 (CYP2D6) phenotype assignment using a genotype algorithm based on allele frequency data. Pharmacogenetics 1999; 9: 669–82
   PubMedGoogle Scholar
• Stamer U. M., Bayerer B., Wolf S., Hoeft A., Stüber F. Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem 2002; 48: 1412–17
   PubMed Web of Science ®Google Scholar
• Løvlie R., Daly A., Molven A., Idle J. R., Steen V. M. Ultrarapid metabolizers of debrisoquine: characterization and PCR‐based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392: 30–4
   PubMed Web of Science ®Google Scholar
• Bjerke J., Chang C‐C., Schur C., Wong S., Nuwayhid N. Genotyping of cytochrome P450 2D6*4 mutation with fluorescent hybridization probes using LightCycler. Rapid cycle real‐time PCR, S Meuer, C Wittwer, K‐I Nakagawara. Springer, New York 2001; 105–10
   Google Scholar
• Kemp C. A., Flanagan J. U., van Eldik A. J., Marechal J. D., Wolf C. R., Roberts G. C. K., et al. Validation of model of cytochrome p450 2D6: an in silico tool for predicting metabolism and inhibition. J Med Chem 2005; 47: 5340–6
   Web of Science ®Google Scholar
• James H. M., Coller J. K., Gillis D., Bahnisch J., Sallustio B. C., Somogyi A. A. A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Intl J Clin Pharmacol Ther 2004; 42: 719–23
   PubMed Web of Science ®Google Scholar
• Eriksson S., Berg L. M., Wadelius M., Alderborn A. Cytochrome P450 genotyping by multiplexed real‐time DNA sequencing with pyrosequencing™ technology. Assay Drug Devel Tech 2002; 1: 49–59
   PubMed Web of Science ®Google Scholar
• Zackrisson A. L., Lindblon B. Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur J Clin Pharmacol 2003; 59: 521–6
   PubMed Web of Science ®Google Scholar
• Murphy G. M., Pollock B. G., Kirshner M. A., Pascoe N., Cheuk W., Mulsant B. H., et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 2001; 25: 737–43
   PubMed Web of Science ®Google Scholar
• Rau T., Heide R., Bergmann K., Wuttke H., Werner U., Feifel N., et al. Effects of the CYP2D6 genotype on metoprolol metabolism persists during long‐term treatment. Pharmacogenetics 2002; 12: 465–72
   PubMedGoogle Scholar
• Gaedigk A., Bradford L. D., Marcucci K. A., Leeder J. S. Unique CYP2D6 activity distribution and genotype–phenotype discordance in black Americans. Clin Pharmacol Ther 2002; 72: 76–89
   PubMed Web of Science ®Google Scholar
• Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284–95
   PubMed Web of Science ®Google Scholar
• Rasmussen J. O., Christensen M., Svendsen J. M., Skausig O., Hansen E. L., Nielsen K. A. CYP2D6 gene test in psychiatric patients and in healthy volunteers. Scand J Clin Lab Invest 2006; 66: 1–8
   PubMed Web of Science ®Google Scholar
• Raimundoo S., Toscano C., Klein K., Fischer J., Griese E–U., Eichelbaum M., et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 CYP2D6 in white subjects. Clin Pharm Ther 2004; 76: 128–38
   PubMed Web of Science ®Google Scholar
• Highsmith W., Jr. SNPs for sale. Cheap! Clin Chem 2004; 50: 1296–8
   PubMed Web of Science ®Google Scholar
• Zhou L., Myers A. N., Vandersteen J. G., Wang L., Wittwer C. T. Closed‐tube genotyping with unlabeled oligonucleotide probes and a saturating DNA dye. Clin Chem 2004; 50: 1328–35
   PubMed Web of Science ®Google Scholar